GI Cancer
Advertisement
ctDNA can serve as a major independent prognostic biomarker in patients with stage III colon cancer after surgery.
Among 16 patients with confirmed recurrence, ctDNA accurately identified recurrence in 15 patients.
Challenges in designing and conducting clinical trials for patients with metastatic pancreatic ductal cancer are discussed.
The efficacy and safety of MEK inhibitors are compared to chemotherapy and other targeted therapies.
The KRAS G12R mutation is analyzed against other alterations in pancreatic adenocarcinoma, and research findings are shared.
Dr. Cytryn summarizes a trial in progress investigating a novel immunotherapy combination for gastroesophageal adenocarcinoma
Drs. Finn and Yopp discuss the challenges of defining high-risk patient populations in adjuvant therapy trials for HCC.
Nivolumab plus ipilimumab provided a higher OS and ORR rate, supporting the combination as a potential standard of care.
The combination was shown to provide a 71% response rate, pointing to a new potential treatment for this patient population.
With an OS rate of about 80%, encorafenib and cetuximab with FOLFOX may serve as a new FDA-approved frontline regimen.
Patients with locally advanced GC who achieved pCR after NAC had significantly better survival outcomes.
Encorafenib with cetuximab was approved by the FDA in 2024 for previously treated patients with BRAF V600E-mutant mCRC.
The panel discusses considerations around treating peritoneal gastric cancer, including the role of HIPEC.
In part three of their discussion, the panel explores the role of ADCs in treating gastric and esophageal cancers.
The panelists discuss the impact of biomarkers on personalized gastric cancer care, including ctDNA, claudin 18.2, and PD-L1.
An expert panel of GI oncologists debates recent advancements in biomarker-driven strategies for GI cancer care.
Dr. Kopetz elaborates on the key efficacy and safety findings, including how they compare to current standard treatments.
A recent retrospective analysis sought to identify novel actionable alterations in patients with SDH-deficient GISTs.
Dr. André elaborates on the efficacy and safety profiles of both treatments and their influence on current therapies.
Dr. Fakih elaborates on the combination's objective response rate, and how it can potentially redefine treatment paradigms.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.